Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR
Hennion & Walsh Asset Management Inc. has acquired a new position in Larimar Therapeutics, Inc. (NASDAQ:LRMR), purchasing 396,726 shares valued at approximately $1.21 million. This makes them a 0.38% owner of the company, with institutional investors collectively holding 91.92% of the stock. Insider activity also includes Director Thomas Edward Hamilton's purchase of 50,000 shares, increasing his holdings by 7.52%.
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR
Dimensional Fund Advisors LP significantly increased its stake in Larimar Therapeutics (NASDAQ:LRMR) by 143.8% in the first quarter, acquiring an additional 470,968 shares to own a total of 798,462 shares valued at approximately $3.6 million. Institutional investors now hold 91.92% of the company's stock. Larimar Therapeutics, a clinical-stage biotechnology company developing a treatment for Friedreich’s ataxia, has a consensus "Buy" rating and a target price of $12.57 from analysts, despite some recent target reductions.
Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR
Renaissance Technologies LLC significantly increased its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 148.9% in the first quarter, now holding 739,942 shares valued at approximately $3.33 million. Institutional investors and hedge funds collectively own 91.92% of LRMR. Insider buying also occurred, with Director Thomas Edward Hamilton purchasing 50,000 shares, while analysts generally maintain a "Buy" rating with an average price target of $12.57.
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
Larimar Therapeutics (LRMR) faces substantial regulatory and manufacturing risks regarding its nomlabofusp drug, impacting its accelerated approval timeline. Delays in BLA submission or issues with third-party manufacturers could postpone commercialization and affect investor confidence. Despite these challenges, Wall Street analysts maintain a Strong Buy consensus rating for LRMR stock.
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
Larimar Therapeutics (LRMR) faces significant regulatory and manufacturing risks for its nomlabofusp drug, impacting its accelerated approval path. Delays in BLA submission or issues with third-party manufacturers, especially those with FDA Form 483 observations, could postpone commercialization and affect investor confidence. Despite these challenges, Wall Street maintains a "Strong Buy" consensus rating on LRMR stock.
Larimar: Q2 Earnings Snapshot
Larimar Therapeutics, Inc. (LRMR) reported a second-quarter loss of $32.8 million, or 30 cents per share. This performance exceeded Wall Street expectations, as analysts surveyed by Zacks Investment Research had estimated a loss of 39 cents per share. The report was generated by Automated Insights using data from Zacks Investment Research.
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary
Larimar Therapeutics reported a net loss of $32.8 million and diluted EPS of $(0.30) for the second quarter of 2026. This represents a widening of net loss compared to the previous year, though the EPS loss improved. The company highlighted significant progress including FDA Breakthrough Therapy designation, completion of early clinical phases, and initiation of commercial readiness for a potential mid-2027 launch.
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Larimar Therapeutics announced its second-quarter 2026 financial and business update, highlighting significant progress in the development of nomlabofusp for Friedreich’s ataxia. Key achievements include positive longer-term open-label study data demonstrating sustained increases in frataxin levels and clinical improvements, initiation of a rolling BLA submission for accelerated approval, and plans to start a global confirmatory Phase 3 study in Q3 2026. The company reported $156.3 million in cash, projecting a runway into Q3 2027, and detailed increased R&D and G&A expenses due to clinical trial activities and commercialization efforts.
SummitTX Capital L.P. Invests $1.71 Million in Larimar Therapeutics, Inc. $LRMR
SummitTX Capital L.P. has acquired a new stake of 379,765 shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR) valued at approximately $1.71 million. This investment comes as other institutional investors have also adjusted their holdings in the company, which has 91.92% institutional ownership. Analyst sentiment for Larimar Therapeutics is largely positive, with a consensus "Buy" rating and a target price of $12.71, despite the stock trading near its 52-week low-to-mid range.
ETFs Investing in Larimar Therapeutics, Inc. Stocks
This article lists various ETFs that currently hold stocks of Larimar Therapeutics, Inc. The ETFs are sorted by their market value and include details such as weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds offering diversified exposure to Larimar Therapeutics with potentially lower risk.
Larimar Therapeutics Inc (LRMR) Institutional Confidence
Larimar Therapeutics Inc (LRMR) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 79.20%, a 23.65% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.34M shares.
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of Larimar Therapeutics Inc (LRMR), noting its weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. The company's financial score is 5.45, ranking it 359 out of 386 in its sector. Several key financial metrics like cash and cash equivalents, total revenue, operating profit, and free cash flow have not been disclosed by the company yet, leading to low scores in profitability, operational efficiency, growth potential, and shareholder returns.
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Larimar Therapeutics Inc (LRMR). It indicates that relevant data for business segments and regional revenue has not yet been disclosed by the company for FY2019. The company's stock information and market capitalization are also presented.
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Larimar Therapeutics Inc's (LRMR) shareholder structure. It lists major shareholders such as Deerfield Management Company and Blue Owl Capital Holdings, categorizes shareholders by type (e.g., Hedge Fund, Investment Advisor), and presents institutional shareholding data over several quarters. Additionally, it highlights recent shareholder activities and lists related ETFs holding LRMR stock.
Larimar Therapeutics Inc (LRMR) Cash Flow
This article provides a detailed historical cash flow statement for Larimar Therapeutics Inc (LRMR), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering investors a comprehensive view of the company's financial health and stability. The content also defines key cash flow terms and highlights LRMR's specific cash flow performance for critical metrics like operating cash flow, capital expenditures, financing cash flow, and free cash flow.
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR
This article focuses on the enterprise value to EBITDA forward metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). It appears to be a financial data presentation rather than an analytical piece, stemming from TradingView. The content provided is minimal, primarily listing the company name and ticker within the context of market data.
TradingKey
This article provides a detailed quarterly and annual income statement for Larimar Therapeutics Inc (LRMR) from FY2012Q4 through FY2026Q1, including metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. It highlights the company's continuous negative net income and operating profit over these periods. The article also includes a FAQ section explaining how to read an income statement and defining key financial terms.
Larimar Therapeutics Market Sentiment
This article analyzes market sentiment for Larimar Therapeutics (LRMR) based on analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts with a high average price target, significant insider buying, but also a notable bearish short interest. The report includes a detailed table of recent analyst actions with their ratings and price targets.
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR
This article provides details on Larimar Therapeutics, Inc. (NASDAQ: LRMR) including its stock market information, financial overviews, and access to documents and news. It indicates that the market is closed without any trades and offers various fundamental and statistical data points like statements, statistics, dividends, earnings, and segment performance. The content is primarily a data portal from TradingView.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) following two significant stock price drops. The investigation focuses on whether the company misled investors regarding the safety of its Friedreich's Ataxia treatment, nomlabofusp, after reports of anaphylaxis were disclosed in clinical trial data. Investors are encouraged to contact Pomerantz LLP for more information.
LRMR|Larimar Therapeutics Inc|Price:4.050|Chg%:+0.040
Larimar Therapeutics Inc (LRMR) is a clinical-stage biotechnology company focusing on treatments for rare diseases, with its lead candidate nomlabofusp targeting Friedreich's ataxia. Despite relatively weak fundamentals and technicals, the company has high growth potential and is considered fairly valued, ranking 135 out of 386 in its industry. Analysts rate LRMR as a "Strong Buy" with a target price of $15.00, representing a significant upside.
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital has reiterated its Buy rating on Larimar Therapeutics (LRMR.US), maintaining its target price at $25. This indicates continued confidence in the company's prospects by the investment firm.
Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71
This article provides financial information for Larimar Therapeutics, Inc. (SWB:ZA71), specifically focusing on its price-to-earnings forward metric. The content highlights the stock's status on the Stuttgart Stock Exchange, indicating it was closed with no trades, and is structured around data from TradingView. It appears to be a stub or a section of a larger financial data platform.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. following two instances where the company's stock price dropped significantly after disclosing anaphylaxis reports in clinical trials for its drug nomlabofusp. The firm is looking into whether Larimar and its officers engaged in unlawful business practices, and encourages affected investors to contact them.
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Larimar Therapeutics (LRMR) has submitted the initial module of its Biologics License Application (BLA) to the U.S. FDA for accelerated approval of its Nomlabofusp therapy, targeting Friedreich's ataxia. The therapy showed positive results in an open-label study, and the FDA confirmed that existing data based on skin frataxin, a new surrogate endpoint, is sufficient for the application. Despite a reduced target price by Baird, the stock still holds significant upside potential.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR | FinancialContent
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors. The investigation stems from two instances where the company's stock price fell significantly after announcing "positive" data from a Friedreich's Ataxia study, which also revealed cases of anaphylaxis among participants. Investors are advised to contact the law firm regarding possible class action involvement.
Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP
This article displays the "Price to earnings forward" for Larimar Therapeutics, Inc. (A2P5PP) on the TradingView platform. It shows that the market for this stock is closed and there have been no trades for this specific financial metric. The content primarily focuses on the display of this financial data point within the TradingView interface.
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy
Larimar Therapeutics Inc. (LRMR) has priced an upsized $100 million stock offering after its shares surged over 60% following the FDA granting Breakthrough Therapy Designation to its frataxin protein replacement therapy, Nomlabofusp, for Friedreich’s ataxia. The funds will support the therapy's development, with a Biologics License Application expected in June and a global confirmatory Phase 3 study to start in Q2 2026. The FDA's decision was based on promising preliminary data showing improved frataxin levels and patient outcomes.
Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics
The article reports that Thomas Hamilton increased his holdings in Larimar Therapeutics by 6.1%. This acquisition suggests a positive outlook on the company's future prospects from a notable investor.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows two significant stock price drops after the company disclosed instances of anaphylaxis in patients using nomlabofusp for Friedreich's Ataxia, despite characterizing the data as "positive." Investors are advised to contact the firm for more information.
Larimar Therapeutics stock jumps on insider purchase By Investing.com
Larimar Therapeutics Inc (NASDAQ:LRMR) shares jumped 15.5% after director Thomas Edward Hamilton purchased 50,000 shares of common stock. The insider acquisition, valued at approximately $166,890, signals confidence in the biopharmaceutical company from a board member. Hamilton now directly owns over 714,000 shares and indirectly holds an additional 159,433 shares.
Enterprise value to revenue forward of Larimar Therapeutics, Inc. – SWB:ZA71
This article provides financial information for Larimar Therapeutics, Inc. (SWB:ZA71) available on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the stock is traded on the Stuttgart Stock Exchange and details various financial and research data sources used.
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
Shares of Larimar Therapeutics, Inc. (LRMR) rose 3% after hours following director Thomas E. Hamilton's purchase of 50,000 shares for approximately $167,000. This insider buying comes as H.C. Wainwright initiated 'Buy' coverage with a $10 price target, anticipating a commercial launch of Larimar's nomlabofusp in 2027 and potential peak annual sales exceeding $1.1 billion by 2040. The company is advancing its Biologics License Application for nomlabofusp, a potential Friedreich's ataxia treatment, with the remaining modules slated for filing in the second half of the year.
Larimar Therapeutics (LRMR) director purchases 50,000 common shares
Larimar Therapeutics director Thomas Edward Hamilton purchased 50,000 common shares in an open-market transaction at a weighted average price of $3.3378 per share. Following this acquisition, Hamilton now directly holds 714,798 common shares and indirectly holds 159,433 shares through Post Edison, LLC. This insider trade is considered to have a moderate, positive filing impact, reflecting increased personal exposure to the company's equity.
If You Invested $1,000 in Larimar Therapeutics Inc (LRMR)
This article analyzes the historical performance of investing $1,000 in Larimar Therapeutics Inc (LRMR) over 1, 5, and 10 years, detailing the returns and compound annual growth rates. It also provides an overview of Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, particularly Friedreich’s ataxia with its lead compound nomlabofusp. The piece covers regulatory interactions, clinical data highlights, safety profiles, and the company's financial strategies.
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
Citi analyst Samantha Semenkow maintained a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target, citing optimism surrounding its lead drug Nomlabofusp for Friedreich’s ataxia. The bullish outlook is driven by upcoming catalysts including new clinical data and a planned rolling FDA submission. The analyst anticipates the drug will achieve a carrier-like state and show continued improvement with good safety results over a full year of data.
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
Shares of Larimar Therapeutics (LRMR) held steady despite recent weakness driven by drug safety concerns, as Wall Street analysts maintained bullish ratings. H.C. Wainwright initiated coverage with a 'Buy' rating and a $10 price target, citing the company's regulatory progress for nomlabofusp, which is expected to launch in 2027 with significant sales potential. Citi also recommended buying LRMR shares, and retail sentiment on Stocktwits remained "extremely bullish."
Price to book forward of Larimar Therapeutics, Inc. – LS:A2P5PP
This article provides financial information for Larimar Therapeutics, Inc. under the stock symbol LS:A2P5PP. It specifically highlights the "Price to book forward" metric. The content appears to be a financial data page from TradingView, indicating that the market is currently closed with no trades.
LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy
HC Wainwright & Co. has initiated coverage on Larimar Therapeutics (LRMR) with a Buy rating and a price target of $10.00, citing confidence in the company's potential despite its current low profitability and growth metrics. Larimar Therapeutics, a clinical-stage biotechnology company, is focused on developing treatments for rare diseases, particularly Friedreich's ataxia. The stock's current trading price of $3.205 suggests it may be undervalued based on the analyst's target, although a comprehensive valuation is limited by the unavailability of GF Value™ data.
Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR
This page from TradingView displays the "Price to book forward" metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). The content indicates the company's financial overview within the health technology and biotechnology sectors. It also includes general disclaimers about market data and copyright information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. on behalf of its investors. The investigation stems from two significant drops in Larimar's stock price following announcements of clinical trial data for its drug nomlabofusp, where "positive" characterizations were overshadowed by disclosures of anaphylaxis in participants. The firm is inviting affected investors to contact them for a potential class action lawsuit.
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP
This article provides access to the enterprise value to EBIT forward data for Larimar Therapeutics, Inc. (LS:A2P5PP) on the TradingView platform. It highlights that the market was closed at the time of access and no trades were recorded. The financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
LRMR Stock Dips As Traders Weigh Cash Runway And Volatility
Larimar Therapeutics Inc. (LRMR) stock fell by 15.16% due to concerns over clinical trial and regulatory updates, closing around $3.11 after an intraday high of $4.30. Despite a strong cash position of $178.5 million, the biotech firm is burning significant cash on R&D, making it a high-risk, high-reward investment. Traders are closely watching its consolidation within the $3.10-$3.70 range for potential breakouts.
Larimar says FDA can review nomlabofusp for accelerated approval
Larimar Therapeutics (LRMR) has submitted the first module of a rolling Biologics License Application (BLA) for accelerated FDA approval of nomlabofusp, a treatment for Friedreich’s ataxia. The FDA noted that existing data, including sustained increases in skin frataxin (FXN) levels and directional clinical improvements, appear sufficient for review, accepting FXN as a potential surrogate endpoint. Despite positive clinical and biomarker trends, the stock declined by 12.57% on the news, partially due to concerns over reported anaphylaxis events in the open-label study.
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug
Larimar Therapeutics' stock fell by 15% despite the FDA backing a rolling Biologics License Application (BLA) submission for nomlabofusp, its rare disease drug for Friedreich's ataxia. The FDA indicated that existing data appears capable of supporting the BLA and agreed to consider frataxin as a novel surrogate endpoint. Long-term study data also showed a durable safety profile and directional improvements in clinical measures for treated patients.
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index
Larimar Therapeutics, Inc. (NasdaqGM:LRMR) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index-related adjustments for the company and other significant corporate updates, including filing the first module of its Biologics License Application (BLA) for nomlabofusp with the US FDA. Larimar Therapeutics is a clinical-stage biotechnology company focused on rare diseases, with its lead candidate nomlabofusp targeting Friedreich's ataxia.
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia
Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp, a treatment for Friedreich’s ataxia. The company expects to submit the remaining BLA modules in the second half of 2026. Open-label data indicates sustained increases in skin frataxin levels and directional clinical improvements, with a safety profile consistent with prior studies.
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics announced the submission of the first module of its rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, a treatment for Friedreich’s ataxia. The company also reported positive long-term open-label study data, showing sustained increases in skin frataxin levels and directional improvements in clinical outcomes for patients treated with nomlabofusp. The FDA has confirmed the sufficiency of the data package to support accelerated approval based on skin frataxin as a potential novel surrogate endpoint.
Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data
Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, citing positive long-term open-label data. The data indicates sustained increases in skin FXN and clinical improvements. The company anticipates submitting remaining modules in the second half of 2026, with a target launch in mid-2027 if approved.
LRMR Stock Slides As Traders Eye Cash Runway And Volatility
Larimar Therapeutics Inc. (LRMR) stock has dropped by 14.62% due to bearish sentiment surrounding its recent clinical developments. Despite concerns over profitability, the company maintains a strong cash position of approximately $178 million, providing a significant runway for operations. Traders are closely monitoring LRMR's volatile intraday action, characterized by sharp premarket gains followed by regular-session fades, highlighting its high-risk, high-reward biotech profile.
